Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aquestive Therapeutics, Inc. - Common Stock
(NQ:
AQST
)
6.040
-0.090 (-1.47%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aquestive Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Aquestive Therapeutics Earnings Preview
October 31, 2022
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
October 27, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
October 24, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
October 19, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Inks Supply Pact For Its Seizure Treatment Covering European, Middle East Countries
September 28, 2022
Via
Benzinga
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
October 11, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ:AQST Investor Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc.
September 29, 2022
San Diego, CA -- (SBWIRE) -- 09/29/2022 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation on over potential breaches of fiduciary duties.
Via
SBWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 28, 2022
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million.
Via
Benzinga
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets
September 28, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive's AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction
September 27, 2022
Via
Benzinga
Where Aquestive Therapeutics Stands With Analysts
September 06, 2022
Aquestive Therapeutics (NASDAQ:AQST) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
September 28, 2022
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 27, 2022
Gainers Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million.
Via
Benzinga
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
September 27, 2022
Aquestive Therapeutics (AQST) stock is taking off Tuesday as investors react to positive clinical trial data from the pharmaceutical company.
Via
InvestorPlace
Why Is Aquestive Therapeutics Stock Up Today?
September 27, 2022
Aquestive Therapeutics Inc (NASDAQ: AQST) shares are trading higher Tuesday after the company announced results from the EPIPHAST II trial for its AQST-109 epinephrine sublingual film.
Via
Benzinga
Aquestive Gets FDA Tentative Approval For Libervant In Seizure Clusters Management
August 31, 2022
The U.S.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 27, 2022
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million.
Via
Benzinga
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
September 08, 2022
Gainers
Via
Benzinga
Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
September 07, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
September 07, 2022
Upgrades
Via
Benzinga
Why Coupa Software Is Trading Higher By Over 12%; Here Are 24 Stocks Moving Premarket
September 07, 2022
Gainers Biophytis S.A. (NASDAQ: BPTS) shares rose 41.5% to $1.33 in pre-market trading after the company announced data on Covid treatment.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 06, 2022
Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average...
Via
Benzinga
FedEx Faces Price Target Cut By This Analyst; Also Check Out Some Other Major PT Changes
September 06, 2022
Citigroup cut the price target on FedEx Corporation (NYSE: FDX) from $270 to $225. Citigroup analyst Christian Wetherbee also downgraded the stock from Buy to Neutral. FedEx shares fell 3% to trade at...
Via
Benzinga
Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday
September 01, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 30, 2022
Via
Benzinga
Why Express Is Trading Higher By Over 21%, Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
August 31, 2022
Gainers Nuwellis, Inc. (NASDAQ: NUWE) shares jumped 140% to $1.5894 after the company announced new clinical data demonstrating 100% survival at 30 days following the use of ultrafiltration in...
Via
Benzinga
NASDAQ:AQST Investor Notice: Update in Lawsuit Against Aquestive Therapeutics, Inc. Announced
August 25, 2022
San Diego, CA -- (SBWIRE) -- 08/25/2022 -- The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST).
Via
SBWire
12 Health Care Stocks Moving In Friday's After-Market Session
August 12, 2022
Via
Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
August 15, 2022
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Via
Benzinga
Aquestive Therapeutics: Q2 Earnings Insights
August 02, 2022
Aquestive Therapeutics (NASDAQ:AQST) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Aquestive Therapeutics...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.